BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29590333)

  • 1. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials.
    Ahmad Y; Howard JP; Arnold A; Shin MS; Cook C; Petraco R; Demir O; Williams L; Iglesias JF; Sutaria N; Malik I; Davies J; Mayet J; Francis D; Sen S
    Eur Heart J; 2018 May; 39(18):1638-1649. PubMed ID: 29590333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
    Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
    Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
    Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yu CM
    Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
    Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
    Pickett CA; Villines TC; Ferguson MA; Hulten EA
    Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
    Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
    Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
    Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
    Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke.
    Kasner SE; Sondergaard L; Nakum M; Gomez Montero M; Hashim M; Landaas EJ
    J Med Econ; 2024; 27(1):337-343. PubMed ID: 38373018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
    Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.
    Kent DM; Saver JL; Kasner SE; Nelson J; Carroll JD; Chatellier G; Derumeaux G; Furlan AJ; Herrmann HC; Jüni P; Kim JS; Koethe B; Lee PH; Lefebvre B; Mattle HP; Meier B; Reisman M; Smalling RW; Soendergaard L; Song JK; Mas JL; Thaler DE
    JAMA; 2021 Dec; 326(22):2277-2286. PubMed ID: 34905030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials.
    Schulze V; Lin Y; Karathanos A; Brockmeyer M; Zeus T; Polzin A; Perings S; Kelm M; Wolff G
    Clin Res Cardiol; 2018 Sep; 107(9):745-755. PubMed ID: 29500568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis.
    Shah R; Nayyar M; Jovin IS; Rashid A; Bondy BR; Fan TM; Flaherty MP; Rao SV
    Ann Intern Med; 2018 Mar; 168(5):335-342. PubMed ID: 29310136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patent foramen ovale closure versus medical therapy after cryptogenic stroke: An updated meta-analysis of all randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Ahmed S; Hassan M; Bachuwa G
    Cardiol J; 2019; 26(1):47-55. PubMed ID: 29512097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis.
    Vukadinović D; Schirmer SH; Vukadinović AN; Ukena C; Scheller B; Mahfoud F; Böhm M
    Clin Res Cardiol; 2019 Feb; 108(2):157-166. PubMed ID: 30051178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.